- Home
- ITOS vs PROK Comparison
ITOS vs PROK Comparison
Compare ITOS & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- PROK
- Stock Information
- Founded
- ITOS 2011
- PROK 2015
- Country
- ITOS United States
- PROK United States
- Employees
- ITOS N/A
- PROK N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ITOS Health Care
- PROK Health Care
- Exchange
- ITOS Nasdaq
- PROK Nasdaq
- Market Cap
- ITOS 446.6M
- PROK 384.2M
- IPO Year
- ITOS 2020
- PROK N/A
- Fundamental
- Price
- ITOS $10.11
- PROK $2.36
- Analyst Decision
- ITOS Hold
- PROK Buy
- Analyst Count
- ITOS 6
- PROK 5
- Target Price
- ITOS $10.40
- PROK $6.25
- AVG Volume (30 Days)
- ITOS 1.6M
- PROK 3.1M
- Earning Date
- ITOS 08-06-2025
- PROK 08-12-2025
- Dividend Yield
- ITOS N/A
- PROK N/A
- EPS Growth
- ITOS N/A
- PROK N/A
- EPS
- ITOS N/A
- PROK N/A
- Revenue
- ITOS N/A
- PROK $527,000.00
- Revenue This Year
- ITOS N/A
- PROK $105.79
- Revenue Next Year
- ITOS N/A
- PROK N/A
- P/E Ratio
- ITOS N/A
- PROK N/A
- Revenue Growth
- ITOS 177.89
- PROK N/A
- 52 Week Low
- ITOS $4.80
- PROK $0.46
- 52 Week High
- ITOS $18.13
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- ITOS 53.14
- PROK 45.54
- Support Level
- ITOS $10.08
- PROK $2.15
- Resistance Level
- ITOS $10.17
- PROK $2.46
- Average True Range (ATR)
- ITOS 0.04
- PROK 0.34
- MACD
- ITOS -0.02
- PROK -0.13
- Stochastic Oscillator
- ITOS 35.29
- PROK 15.00
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.